Edwards Lifesciences EBITDA Margin 2010-2022 | EW

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Edwards Lifesciences (EW) over the last 10 years. The current EBITDA margin for Edwards Lifesciences as of June 30, 2022 is .
Edwards Lifesciences EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2022-06-30 $5.36B $1.80B 33.58%
2022-03-31 $5.36B $1.88B 35.13%
2021-12-31 $5.23B $1.83B 34.87%
2021-09-30 $5.10B $1.80B 35.37%
2021-06-30 $4.93B $1.76B 35.75%
2021-03-31 $4.48B $1.04B 23.20%
2020-12-31 $4.39B $1.01B 22.91%
2020-09-30 $4.37B $0.96B 21.88%
2020-06-30 $4.32B $0.89B 20.59%
2020-03-31 $4.48B $1.32B 29.53%
2019-12-31 $4.35B $1.24B 28.43%
2019-09-30 $4.15B $0.92B 22.06%
2019-06-30 $3.97B $0.87B 21.87%
2019-03-31 $3.82B $0.85B 22.21%
2018-12-31 $3.72B $0.83B 22.18%
2018-09-30 $3.64B $1.14B 31.28%
2018-06-30 $3.55B $1.12B 31.46%
2018-03-31 $3.45B $1.11B 32.31%
2017-12-31 $3.44B $1.17B 34.10%
2017-09-30 $3.32B $1.04B 31.27%
2017-06-30 $3.23B $1.00B 31.02%
2017-03-31 $3.15B $0.97B 30.73%
2016-12-31 $2.96B $0.86B 28.89%
2016-09-30 $2.87B $0.85B 29.80%
2016-06-30 $2.74B $0.81B 29.68%
2016-03-31 $2.60B $0.75B 28.64%
2015-12-31 $2.49B $0.71B 28.39%
2015-09-30 $2.44B $0.69B 28.19%
2015-06-30 $2.43B $0.66B 27.22%
2015-03-31 $2.39B $0.63B 26.49%
2014-12-31 $2.32B $0.56B 24.20%
2014-09-30 $2.24B $0.54B 24.02%
2014-06-30 $2.13B $0.51B 24.10%
2014-03-31 $2.07B $0.52B 25.06%
2013-12-31 $2.05B $0.54B 26.15%
2013-09-30 $2.02B $0.55B 26.98%
2013-06-30 $1.97B $0.53B 26.93%
2013-03-31 $1.94B $0.50B 25.81%
2012-12-31 $1.90B $0.47B 24.96%
2012-09-30 $1.82B $0.42B 23.09%
2012-06-30 $1.78B $0.39B 21.58%
2012-03-31 $1.73B $0.37B 21.06%
2011-12-31 $1.68B $0.36B 21.32%
2011-09-30 $1.64B $0.35B 21.51%
2011-06-30 $1.58B $0.36B 22.83%
2011-03-31 $1.51B $0.36B 23.63%
2010-12-31 $1.45B $0.34B 23.57%
2010-09-30 $1.40B $0.32B 23.11%
2010-06-30 $1.38B $0.32B 22.84%
2010-03-31 $1.35B $0.31B 22.59%
2009-12-31 $1.32B $0.30B 22.45%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $54.208B $5.233B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $214.023B 21.80
Alcon (ALC) Switzerland $30.150B 25.53
STERIS (STE) Ireland $17.307B 21.50
Teleflex (TFX) United States $9.641B 15.36
Fresenius Medical Care AG KGaA (FMS) Germany $8.287B 7.64
Penumbra (PEN) United States $7.435B 891.96
Globus Medical (GMED) United States $6.225B 31.75
Glaukos (GKOS) United States $2.693B 0.00
Integer Holdings (ITGR) United States $2.196B 17.17
Nevro (NVRO) United States $1.739B 0.00
Paragon 28 (FNA) United States $1.384B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.081B 16.55
Artivion (AORT) United States $0.519B 49.50